Company intelligence / Profile preview

Prism Pharmaceuticals

King Of Prussia, Pennsylvania, United Statesprismpharmamachinery.com ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Prism Pharmaceuticals was a specialty pharmaceutical company focused on developing and commercializing acute care injectable products for cardiovascular indications. Its lead product, NEXTERONE (amiodarone hydrochloride), received FDA approval. The company was acquired by Baxter International, after which it ceased independent operations.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Investors included Baxter InternationalEW Healthcare PartnersHealthCare Royalty PartnersPaul Capital Partners

Beyond the preview

Go deeper on Prism Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prism Pharmaceuticals.

Explore the full profile